[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vitebsk Regional Clinical Cancer Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100574680","phase-iii-open-label-study-evaluating-the-safety-and-efficacy-of-concomitant-administration-of-anti-cd19-car-t-cell-therapy-and-lenalidomide-in-refractoryrelapsed-chronic-lymphocytic-leukemia-patients-100574680",false,"NCT06762431","Phase I\u002FII Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory\u002FRelapsed Chronic Lymphocytic Leukemia Patients.","VTB-CLL002","Inclusion Criteria:\n\n* Documented CD19+ CLL or SLL\n* Patients must have failed at least 1 prior regimen\n* Patients must be currently receiving ibrutinib for at least 3 months prior to enrollment in the study and:\n* Not experiencing any ≥ grade 2 non-hematologic ibrutinib-related toxicity\n* ECOG Performance status 0 or 1\n* 18 years of age and older\n* Adequate organ system function including:\n\nCreatinine \\\u003C 1.6 mg\u002Fdl ALT\u002FAST \\\u003C 3x upper limit of normal Total Bilirubin \\\u003C2.0 mg\u002Fdl with the exception of patients with Gilbert syndrome; patients with Gilbert syndrome may be included if their total bilirubin is ≥ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN.\n\n* Have no active GVHD and require no immunosuppression\n* Are more than 6 months from transplant\n* No contraindications for leukapheresis\n* Left Ventricular Ejection fraction \\>50%\n* Gives informed consent\n\nExclusion Criteria:\n\n* CLL patients with known or suspected transformed disease (i.e. Richter's transformation).\n* Pregnant or lactating women.\n* Uncontrolled active infection.\n* Active hepatitis B or hepatitis C infection.\n* Concurrent use of systemic steroids or chronic use of immunosuppressant medications.\n* Any uncontrolled active medical disorder\n* HIV infection.\n* Patients with active CNS involvement with malignancy.\n* Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n* Subjects with clinically apparent arrhythmia or arrhythmias who are not stable","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a Phase I\u002FII interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed\u002Frefractory chronic lymphocytic leukemia (CLL) who have been pretreated with Ibrutinib for 3 months prior to leukapheresis.",[27,28],"Chronic Lymphocytic Leukaemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[30,31,32],"anti-CD19 CAR T-cells","Lenalidomide","Ibrutinib","RECRUITING","2026-08-12",{"date":36,"type":37},"2026-08-13","ACTUAL",{"date":39,"type":37},"2024-05-14",{"date":41,"type":20},"2026-08-31",{"name":43,"class":44},"Vitebsk Regional Clinical Cancer Centre","OTHER",""]